PandaOmics is a SaaS software platform developed by Insilico Medicine that leverages the power of deep learning AI algorithms to discover therapeutic targets associated with a specific disease. The platform analyzes omics data and combines it with prior information from various sources such as publications, clinical trials, and grant applications. The algorithms used by PandaOmics consider multiple factors, including novelty, confidence, commercial tractability, druggability, safety, and other essential properties that influence the selection of therapeutic targets. PandaOmics has been instrumental in identifying new targets for various diseases, including cancer, Amyotrophic Lateral Sclerosis (ALS), COVID-19, and related variants. Its discovery of a novel target for idiopathic pulmonary fibrosis has led to the development of a lead drug candidate designed through Insilico Medicine's Chemistry42 platform, which has successfully completed Phase 1 clinical trials. This achievement marks the first AI-designed and AI-discovered drug to reach this milestone.
Course attendees are provided with free access to the demo version of PandaOmics. Do not miss your chance to try the best software for cutting-edge research in drug development!